Joel Picus

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006
    Joel Picus
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer 117:526-33. 2011
  2. pmc Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer
    Robert J Myerson
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri Electronic address
    Int J Radiat Oncol Biol Phys 88:829-36. 2014
  3. doi request reprint Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study
    David C Linehan
    Department of Surgery, Barnes Jewish Hospital Washington University Medical Center and Siteman Cancer Center, St Louis, Missouri 63110, USA
    Ann Surg 248:145-51. 2008
  4. ncbi request reprint Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
    Adam S Kibel
    Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
    J Urol 177:1777-81. 2007
  5. doi request reprint Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma
    Parvin F Peddi
    Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA
    JOP 13:497-501. 2012
  6. doi request reprint Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 63:451-8. 2009
  7. ncbi request reprint Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 25:565-70. 2007
  8. ncbi request reprint A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008
    Walter M Stadler
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 107:1273-9. 2006
  9. pmc A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Paula M Fracasso
    Department of Internal Medicine, Alvin J Siteman Cancer Center and Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 67:1225-37. 2011
  10. doi request reprint Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience
    Robert J Myerson
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 75:428-35. 2009

Collaborators

Detail Information

Publications26

  1. pmc A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006
    Joel Picus
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer 117:526-33. 2011
    ..Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in patients with CRPC...
  2. pmc Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer
    Robert J Myerson
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri Electronic address
    Int J Radiat Oncol Biol Phys 88:829-36. 2014
    ....
  3. doi request reprint Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study
    David C Linehan
    Department of Surgery, Barnes Jewish Hospital Washington University Medical Center and Siteman Cancer Center, St Louis, Missouri 63110, USA
    Ann Surg 248:145-51. 2008
    ..The primary end point was 2-year overall survival, with secondary endpoints being 2-year disease-free survival, and the frequency of grade 3 or 4 toxicity...
  4. ncbi request reprint Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
    Adam S Kibel
    Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
    J Urol 177:1777-81. 2007
    ..Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients...
  5. doi request reprint Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma
    Parvin F Peddi
    Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA
    JOP 13:497-501. 2012
    ..Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial...
  6. doi request reprint Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 63:451-8. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate...
  7. ncbi request reprint Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 25:565-70. 2007
    ..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity...
  8. ncbi request reprint A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008
    Walter M Stadler
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 107:1273-9. 2006
    ..The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting...
  9. pmc A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Paula M Fracasso
    Department of Internal Medicine, Alvin J Siteman Cancer Center and Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 67:1225-37. 2011
    ..We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pharmacodynamic effects of UCN-01 and irinotecan in patients with resistant solid tumors...
  10. doi request reprint Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience
    Robert J Myerson
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 75:428-35. 2009
    ..To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma...
  11. ncbi request reprint Positron tomographic assessment of androgen receptors in prostatic carcinoma
    Farrokh Dehdashti
    The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, 63110, USA
    Eur J Nucl Med Mol Imaging 32:344-50. 2005
    ....
  12. pmc A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
    Andrea Wang-Gillam
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Invest New Drugs 31:707-13. 2013
    ....
  13. pmc A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Cynthia X Ma
    Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, Campus Box 8056, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Breast Cancer Res Treat 137:483-92. 2013
    ..5 vs. 20.3 months, p = 0.004). This regimen had limited activity in TNBC. Inconsistent Chk1 inhibition was likely due to the pharmacokinetics of UCN-01. TP53 mutations were associated with a poor prognosis in metastatic TNBC...
  14. pmc Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study
    Kerry J Williams
    Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MI 63110, USA
    HPB (Oxford) 12:418-26. 2010
    ..The aim of this phase II single-institution trial was to assess the efficacy and safety of gemcitabine combined with carboplatin in the first-line treatment of patients with advanced BTCs...
  15. doi request reprint Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782
    J Paul Monk
    Division of Oncology, Department of Medicine, The Ohio State University School of Medicine, Columbus, Ohio, USA
    Cancer 118:4139-47. 2012
    ..Because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression...
  16. ncbi request reprint A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma
    Lilie L Lin
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Am J Clin Oncol 28:234-41. 2005
    ..Despite the prolongation in radiation treatment time because of split-course treatment, patients with sufficient response were able to undergo resection...
  17. ncbi request reprint Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480
    Peter A Humphrey
    Washington University Medical Center, St Louis, MO 63110, USA
    Clin Genitourin Cancer 4:269-74. 2006
    ..Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma...
  18. ncbi request reprint 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse
    Nobuyuki Oyama
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Boulevard, St Louis, MO 63110, USA
    J Nucl Med 44:549-55. 2003
    ..We also compared the reliability of AC PET in detecting recurrent prostate cancer with that of PET with (18)F-FDG...
  19. ncbi request reprint Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors
    Alexander S Ho
    Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, Saint Louis, MO 63110, USA
    AJR Am J Roentgenol 188:1201-7. 2007
    ..Long-term outcome data are limited. We present our experience in the use of hepatic artery chemoembolization in the treatment of patients with hepatic metastasis from neuroendocrine tumors...
  20. ncbi request reprint Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, St Louis, Missouri 63110, USA
    Cancer 98:610-7. 2003
    ..The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with advanced malignancies...
  21. ncbi request reprint A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 61:453-8. 2008
    ..Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC...
  22. ncbi request reprint CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma
    Adam S Kibel
    Departments of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer Res 63:2033-6. 2003
    ..Analysis of CDKN1A and/or CDKN1B genotypes may prove useful in determining which patients are at risk for developing advanced prostate carcinoma and therefore would gain the most from aggressive screening, prophylaxis, and/or treatment...
  23. ncbi request reprint The role of primary chemotherapy for prostate cancer: has the time come?
    P Paula Hruska
    Siteman Cancer Center, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA
    Curr Urol Rep 7:233-8. 2006
    ..Further investigation through prospective, randomized trials is critical to define the precise role of this modality in high-risk populations...
  24. ncbi request reprint Evaluating risk factors for the development of ifosfamide encephalopathy
    Kevin A David
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Am J Clin Oncol 28:277-80. 2005
    ..The goal of this review is to identify the prevalence of ifosfamide encephalopathy at Barnes-Jewish Hospital from 1995 to 2003, and to identify risk factors associated with the condition...
  25. ncbi request reprint Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma
    Robert Myerson
    Department of Radiation Oncology, and the Divisions of Colorectal Surgery and Medical Oncology, Washington University School of Medicine, St Louis, MO 63110 1001, USA
    Semin Oncol 29:29-33. 2002
    ..These very early results suggest that the use of amifostine does not interfere with tumor response and that it may facilitate the delivery of higher boost doses to the rectum...
  26. ncbi request reprint Severe interstitial pneumonitis associated with docetaxel administration
    William L Read
    Department of Medicine, Division of Medical Oncology at Washington University, St Louis, Missouri, USA
    Cancer 94:847-53. 2002
    ..Interstitial pneumonitis has not been reported as a toxicity of docetaxel. The authors report the presentation and natural history of four patients who developed a severe interstitial pneumonitis after receiving docetaxel...